UrsaNav trials eLoran as vital GNSS backup using ADVA’s grandmaster clock solution
27.7.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that UrsaNav and ADVA have conducted an enhanced long-range navigation (eLoran) field trial using UrsaNav’s eLoran receiver and ADVA’s Oscilloquartz grandmaster clock technology. The successful demo shows that eLoran offers a robust and reliable backup for GPS and other GNSS and could be used to provide an assured position, navigation, and timing (PNT) service. The trial follows US federal executive order 13905 aimed at strengthening national resilience through PNT services, including protecting critical infrastructure such as electrical power grid and communication networks from rising cyber threats. By harnessing ADVA’s flexible OSA 5420 Series, designed with assured PNT (aPNT) technology, UrsaNav has shown that eLoran can provide a new layer of protection and significantly boost timing resilience and security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005101/en/
ADVA’s synchronization technology is key for critical infrastructure that needs ultra-reliable aPNT solutions (Photo: Business Wire)
“The success of this field trial demonstrates how eLoran, as part of ADVA’s assured PNT solution, can serve as a crucial backup for GPS. We have shown how our technology enables ADVA’s grandmaster clock to receive UTC timing from the eLoran system for a period of several days with the same accuracy and stability as GPS. Of course, this capability is extensible to other GNSS as well. eLoran is far less vulnerable to unintentional jamming and spoofing disruptions or intentional attacks, thereby delivering nanosecond precision with even more resilience,” said Charles Schue, CEO, UrsaNav. “By partnering with ADVA, we’ve been able to show that our eLoran receiver interoperates with the best network timing toolkit available. The OSA 5420 Series is a great product – highly efficient and easy to operate. Together with ADVA, we’re paving the way for tomorrow’s more robust assured PNT synchronization architecture.”
Across the globe, essential services and entire industries are increasingly reliant on GNSS for PNT information. But these satellite systems are inherently susceptible to interference, which could have disastrous consequences. A major disruption may result in billions of dollars of economic damage as well as a serious risk of loss of life. eLoran is one of the key technologies that could provide protection, with governments including the US exploring its potential as an alternative PNT source. UrsaNav’s latest trial harnessed the OSA 5420 Series grandmaster clock with inbuilt GNSS receiver. Timing stability from GPS was measured for several days. This was then replaced with eLoran for the same period with no loss of stability. What’s more, the test was conducted indoors where GNSS signals are not usually available, potentially extending the availability of precise UTC timing to many more environments.
“Commercially available GNSS jammers and spoofers are easy and cheap for attackers to construct. That’s part of the reason why we’re seeing a growing number of incidents across the world of blocked or misleading signals. If power utilities, enterprises, service providers and governments continue to rely on GNSS alone, it’s only a matter of time before the consequences become very serious. That’s why we’re committed to tackling GNSS vulnerabilities with advanced technologies like our ePRTC offering, cesium atomic clocks and our optical timing channel solution,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Now that UrsaNav has demonstrated the power of our OSA 5420 Series to utilize eLoran in the event of outages, we have another very important tool to ensure the quality and availability of time-sensitive services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
About UrsaNav
Ursa Navigation Solutions (“UrsaNav”) is the world’s leading supplier of Low Frequency PNT solutions, with proven performance delivering the latest technology for eLoran systems, including transmission, control, monitoring, and reference site equipment. From initial concept through operational certification, UrsaNav provides every aspect of the provider or user experience, including commercial and military PNT solutions, critical infrastructure protection, and legacy system transformation. www.ursanav.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005101/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
